Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Salk

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
Nature|January 24, 1970
Increases in serum lactate dehydrogenase in experimental allergic encephalomyelitisA E Kaplan, L V Brown, J Salk
Cancer Research|June 11, 2009
Cancer genome sequencing--an interim analysisEdward J Fox, Jesse J Salk, Lawrence A Loeb
Annual Review of Pathology|September 12, 2009
Mutational heterogeneity in human cancers: origin and consequencesJesse J Salk, Edward J Fox, Lawrence A Loeb
Nature Reviews. Genetics|March 27, 2018
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutationsJesse J Salk, Michael W Schmitt, Lawrence A Loeb
Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1985
Pseudotumour cerebri and the Turner syndromeV P Sybert, T D Bird, D J Salk
Aging Cell|June 5, 2014
Response to: 'when man got his mtDNA deletions?'Sean D Taylor, Jesse J Salk, Jason H Bielas
American Journal of Medical Genetics|January 1, 1981
Brief clinical report: the del(4) (q31) syndrome- a recognizable disorder with atypical Robin malformation sequenceJ M Davis, S K Clarren, D J Salk
Genome Medicine|March 19, 2016
Exploring the implications of distinct mutational signatures and mutation rates in aging and cancerEdward J Fox, Jesse J Salk, Lawrence A Loeb
Nature Reviews. Clinical Oncology|October 21, 2015
The influence of subclonal resistance mutations on targeted cancer therapyMichael W Schmitt, Lawrence A Loeb, Jesse J Salk
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Risks of double-counting in deep sequencingMichael W Schmitt, Edward J Fox, Jesse J Salk
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Nature|January 24, 1970
Increases in serum lactate dehydrogenase in experimental allergic encephalomyelitisA E Kaplan, L V Brown, J Salk
Cancer Research|June 11, 2009
Cancer genome sequencing--an interim analysisEdward J Fox, Jesse J Salk, Lawrence A Loeb
Annual Review of Pathology|September 12, 2009
Mutational heterogeneity in human cancers: origin and consequencesJesse J Salk, Edward J Fox, Lawrence A Loeb
Nature Reviews. Genetics|March 27, 2018
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutationsJesse J Salk, Michael W Schmitt, Lawrence A Loeb
Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1985
Pseudotumour cerebri and the Turner syndromeV P Sybert, T D Bird, D J Salk
Aging Cell|June 5, 2014
Response to: 'when man got his mtDNA deletions?'Sean D Taylor, Jesse J Salk, Jason H Bielas
American Journal of Medical Genetics|January 1, 1981
Brief clinical report: the del(4) (q31) syndrome- a recognizable disorder with atypical Robin malformation sequenceJ M Davis, S K Clarren, D J Salk
Genome Medicine|March 19, 2016
Exploring the implications of distinct mutational signatures and mutation rates in aging and cancerEdward J Fox, Jesse J Salk, Lawrence A Loeb
Nature Reviews. Clinical Oncology|October 21, 2015
The influence of subclonal resistance mutations on targeted cancer therapyMichael W Schmitt, Lawrence A Loeb, Jesse J Salk
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Risks of double-counting in deep sequencingMichael W Schmitt, Edward J Fox, Jesse J Salk
Pageof 12